Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis

The efficacy of second-line treatment in patients with epidermal growth factor receptor (EGFR) wild-type tumours is still debatable. We assessed the efficacy of a standard second-line chemotherapy compared with erlotinib in an individual patient data approach for meta-analysis. The primary endpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Garassino, Marina Chiara, Kawaguchi, Tomoya, Gregorc, Vanesa, Rulli, Eliana, Ando, Masahiko, Marsoni, Silvia, Isa, Shun-ichi, Novello, Silvia, Farina, Gabriella, Barni, Sandro, Torri, Valter, Cinquini, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267321/
https://www.ncbi.nlm.nih.gov/pubmed/30555723
http://dx.doi.org/10.1136/esmoopen-2018-000327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267321/
https://www.ncbi.nlm.nih.gov/pubmed/30555723
http://dx.doi.org/10.1136/esmoopen-2018-000327

Ejemplares similares